SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla Medpro wins R2 billion share of South African Government’s ARV tender

23 Dec 2014 Evaluate

Cipla Medpro, 100%-owned by Cipla, has been awarded R2 billion share of the South African Government’s 2015-17 National ARV tender. The contract is effective from the April 1, 2015 and will run for a period of three years.

This latest Government tender win is the third in the last year for the growing pharmaceutical company, and follows Cipla Medpro winning a R280 million state therapeutic drug tender (August 2014), a R345 million national respiratory tender (June 2014).

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×